Literature DB >> 27141334

Novel therapy of prostate cancer employing a combination of viral-based immunotherapy and a small molecule BH3 mimetic.

Siddik Sarkar1, Anjan Pradhan1, Swadesh K Das2, Luni Emdad2, Devanand Sarkar2, Maurizio Pellecchia3, Paul B Fisher2.   

Abstract

Cancer-selective viral replication and delivery of a therapeutic immunomodulating, cancer-selective killing cytokine (mda-7/IL-24) by means of a new Cancer Terminator Virus (CTV) combined with a small molecule BH3 mimetic holds promise for treating both primary and metastatic hormone refractory prostate cancer (CaP).

Entities:  

Keywords:  Cancer Terminator Virus (CTV); MDA-7/IL-24; Primary and Metastatic Prostate Cancer; Sabutoclax; Tumor-Specific Apoptosis; Immunotherapy; Ultrasound-Targeted Microbubble-Destruction (UTMD)

Year:  2015        PMID： 27141334      PMCID： PMC4839355          DOI： 10.1080/2162402X.2015.1078059

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells.

Authors:  Zhaozhong Su; Luni Emdad; Moira Sauane; Irina V Lebedeva; Devanand Sarkar; Pankaj Gupta; C David James; Aaron Randolph; Kirstoffer Valerie; Mark R Walter; Paul Dent; Paul B Fisher
Journal:  Oncogene       Date:  2005-11-17       Impact factor: 9.867

2.  Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.

Authors:  Devanand Sarkar; Zao-Zhong Su; Nicolaq Vozhilla; Eun Sook Park; Pankaj Gupta; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

3.  Eradication of therapy-resistant human prostate tumors using a cancer terminator virus.

Authors:  Devanand Sarkar; Irina V Lebedeva; Zao-zhong Su; Eun-Sook Park; Lejuan Chatman; Nicollaq Vozhilla; Paul Dent; David T Curiel; Paul B Fisher
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

Review 4.  Chapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.

Authors:  Swadesh K Das; Siddik Sarkar; Rupesh Dash; Paul Dent; Xiang-Yang Wang; Devanand Sarkar; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

5.  Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression.

Authors:  Hyo-eun C Bhang; Kathleen L Gabrielson; John Laterra; Paul B Fisher; Martin G Pomper
Journal:  Nat Med       Date:  2010-12-12       Impact factor: 53.440

6.  Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61.

Authors:  L G Harris; L K Pannell; S Singh; R S Samant; L A Shevde
Journal:  Oncogene       Date:  2011-11-07       Impact factor: 9.867

7.  An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic bcl-2 family proteins.

Authors:  Jun Wei; John L Stebbins; Shinichi Kitada; Rupesh Dash; Dayong Zhai; William J Placzek; Bainan Wu; Michele F Rega; Ziming Zhang; Elisa Barile; Li Yang; Russell Dahl; Paul B Fisher; John C Reed; Maurizio Pellecchia
Journal:  Front Oncol       Date:  2011-09-30       Impact factor: 6.244

8.  Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.

Authors:  Siddik Sarkar; Bridget A Quinn; Xue-Ning Shen; Rupesh Dash; Swadesh K Das; Luni Emdad; Alexander L Klibanov; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Oncotarget       Date:  2015-05-10

Review 9.  mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.

Authors:  Rupesh Dash; Sujit K Bhutia; Belal Azab; Zhao-zhong Su; Bridget A Quinn; Timothy P Kegelmen; Swadesh K Das; Keetae Kim; Seok-Geun Lee; Margaret A Park; Adly Yacoub; Mohammed Rahmani; Luni Emdad; Igor P Dmitriev; Xiang-Yang Wang; Devanand Sarkar; Steven Grant; Paul Dent; David T Curiel; Paul B Fisher
Journal:  Cytokine Growth Factor Rev       Date:  2010-10       Impact factor: 7.638

10.  Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.

Authors:  Rupesh Dash; Belal Azab; Bridget A Quinn; Xuening Shen; Xiang-Yang Wang; Swadesh K Das; Mohamed Rahmani; Jun Wei; Michael Hedvat; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Bainan Wu; John L Stebbins; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205
  10 in total
  4 in total

1.  Nanoparticle Design Strategies for Effective Cancer Immunotherapy.

Authors:  Praveena Velpurisiva; Aniket Gad; Brandon Piel; Rahul Jadia; Prakash Rai
Journal:  J Biomed (Syd)       Date:  2017

Review 2.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 3.  Physiological and Pharmacological Control of BAK, BAX, and Beyond.

Authors:  Mark P A Luna-Vargas; Jerry Edward Chipuk
Journal:  Trends Cell Biol       Date:  2016-08-04       Impact factor: 20.808

4.  Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor.

Authors:  Anjan K Pradhan; Praveen Bhoopathi; Santanu Maji; Amit Kumar; Chunqing Guo; Padmanabhan Mannangatti; Jiong Li; Xiang-Yang Wang; Devanand Sarkar; Luni Emdad; Swadesh K Das; Paul B Fisher
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.